Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 9%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

10x Genomics is expected to experience growth in the coming years, with a new avenue for growth outlined in the Los Reyes PEA and fully fundable from current liquidity and Morelos cash flow with a value step up. Although Q2 production came in below estimates, FY2026 guidance was reiterated and Media Luna is on track to deliver first ore before year-end 2026. Additionally, the company's high-quality and high-sensitivity data from the Chromium platform are expected to maintain market share against new entrants, positioning 10x as a premier asset in the genomics space. However, risks include a reduction in adoption and usage momentum due to constrained research funding and increased competition, and the company requires significant investment in R&D and SG&A. Overall, our outlook for 10x Genomics is positive, with an EV/Sales multiple of ~3.5x applied to our 2026 revenue estimate of $618M for a target price of $20/share.

Bears say

10x Genomics is facing a potential dip in instruments sales due to competitors' pricing strategy. The company's Visium platform may also experience a decline in performance due to increased competition. Additionally, the company is heavily reliant on consumable-driven package deals to maintain instrument placements, which may put pressure on average selling prices. Furthermore, the company's push into the translational and clinical space, AI-driven data generation, and extension into CLIA-certified laboratory services may not gain significant uptake and adoption as expected, potentially impacting future revenue growth. These factors, coupled with the company's high operating expenses, suggest a potential decline in profitability in the coming years.

10X Genomics (TXG) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 9% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 11 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.